Literature DB >> 8215289

Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene.

R F Schinazi1, R Sijbesma, G Srdanov, C L Hill, F Wudl.   

Abstract

The bis(monosuccinimide) derivative of p,p'-bis(2-aminoethyl)diphenyl-C60 (compound 1), prepared by the fulleroid route, is active against human immunodeficiency virus type 1 (HIV-1) and HIV-2 (50% effective concentration [EC50] averaging approximately 6 microM) in acutely or chronically infected human lymphocytes and is active in vitro against 3'-azido-3'-deoxythymidine-resistant HIV-1 (EC50, approximately 3 microM). The virucidal properties of compound 1 were confirmed by virus inactivation assays. Compound 1 was noncytotoxic up to 100 microM in peripheral blood mononuclear cells and H9, Vero, and CEM cells. In cell-free assays, whereas the fullerene showed comparable activity against HIV-1 reverse transcriptase and DNA polymerase alpha (50% inhibitory concentration of approximately 5 microM), it demonstrated selective activity against HIV-1 protease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215289      PMCID: PMC188048          DOI: 10.1128/AAC.37.8.1707

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  HIV drug resistance.

Authors:  D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

2.  Molecule of the year.

Authors:  D E Koshland
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

3.  Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1.

Authors:  T J Bardos; R F Schinazi; K H Ling; A R Heider
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

5.  Fullerenes from the geological environment.

Authors:  P R Buseck; S J Tsipursky; R Hettich
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

6.  Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.

Authors:  M R Posner; H S Elboim; T Cannon; L Cavacini; T Hideshima
Journal:  AIDS Res Hum Retroviruses       Date:  1992-05       Impact factor: 2.205

7.  Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S.

Authors:  E Ido; H P Han; F J Kezdy; J Tang
Journal:  J Biol Chem       Date:  1991-12-25       Impact factor: 5.157

8.  Systematic inflation of buckminsterfillerene c60: synthesis of diphenyl fulleroids c61 to c66.

Authors:  T Suzuki; Q Li; K C Khemani; F Wudl; O Almarsson
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

9.  Discovery and characterization of an HIV-1 Tat antagonist.

Authors:  M C Hsu; A D Schutt; M Holly; L W Slice; M I Sherman; D D Richman; M J Potash; D J Volsky
Journal:  Biochem Soc Trans       Date:  1992-05       Impact factor: 5.407

10.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  R F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; M St Clair; J Wilson; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more
  18 in total

1.  In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers.

Authors:  D W Cagle; S J Kennel; S Mirzadeh; J M Alford; L J Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.

Authors:  Zachary S Martinez; Edison Castro; Chang-Soo Seong; Maira R Cerón; Luis Echegoyen; Manuel Llano
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Virucidal agents in the eve of manorapid synergy.

Authors:  Angel S Galabov
Journal:  GMS Krankenhhyg Interdiszip       Date:  2007-09-13

5.  Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.

Authors:  Biswa Ranjan Meher; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2012-10-13       Impact factor: 2.518

6.  Pharmacokinetics of a water-soluble fullerene in rats.

Authors:  P Rajagopalan; F Wudl; R F Schinazi; F D Boudinot
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Cationic fullerenes are effective and selective antimicrobial photosensitizers.

Authors:  George P Tegos; Tatiana N Demidova; Dennisse Arcila-Lopez; Haeryeon Lee; Tim Wharton; Hariprasad Gali; Michael R Hamblin
Journal:  Chem Biol       Date:  2005-10

8.  Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics.

Authors:  B X Chen; S R Wilson; M Das; D J Coughlin; B F Erlanger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Difference in phototoxicity of cyclodextrin complexed fullerene [(gamma-CyD)2/C60] and its aggregated derivatives toward human lens epithelial cells.

Authors:  Baozhong Zhao; Yu-Ying He; Colin F Chignell; Jun-Jie Yin; Usha Andley; Joan E Roberts
Journal:  Chem Res Toxicol       Date:  2009-04       Impact factor: 3.739

10.  Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells.

Authors:  Joan E Roberts; Albert R Wielgus; William K Boyes; Usha Andley; Colin F Chignell
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-15       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.